In a swift turnaround, Sarepta announced that it has cleared the FDA’s concerns about its gene therapy program for Duchenne muscular dystrophy, convincing regulators to lift a clinical hold issued just two months ago.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,